EGFR and cancer: Recent clinical studies have demonstrated an objective response in patients with several types of cancers treated either by blocking EGFR with monoclonal antibodies (cetuximab, panitumumab, etc.)or by inhibiting EGFR tyrosine kinase activity with small-molecule inhibitors (gefitinib, erlotinib, etc.)[4]–[9].